The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer

J. Kellogg Parsons1, John P. Pierce2, James Mohler3, Electra Paskett4, Sin-Ho Jung5, Michael J. Morris5, Eric Small7, Olwen Hahn5, Peter Humphrey9, John Taylor8, and James Marshall10

1. Division of Urologic Oncology, UC San Diego Moores Comprehensive Cancer Center; Department of Urology, UC San Diego Health System; and VA San Diego Healthcare System, La Jolla, CA
2. Department of Family Medicine and Public Health and Moores Cancer Center, University of California, San Diego, La Jolla, CA
3. Department of Urology, Roswell Park Cancer Institute, Buffalo, NY
4. Department of Medicine, College of Medicine, Comprehensive Cancer Center, Ohio State University, Columbus, OH
5. Alliance Statistics and Data Center, Duke University, Durham, NC
6. Memorial Sloan Kettering Cancer Center, New York, NY
7. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
8. Alliance Central Protocol Operations, University of Chicago, Chicago, IL
9. Department of Pathology, Yale University Medical School, New Haven, CT
10. Department of Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY

Background: Diet may influence the risks of prostate cancer incidence and progression. However, large-scale randomized trials of dietary interventions for prostate cancer have yet to be completed.

Methods: The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]) is a phase 3 clinical trial testing the efficacy of a high-vegetable diet to prevent progression in prostate cancer patients on active surveillance. Participants were randomized to a validated diet counseling intervention or a control condition. Chi-Square and Kruskal Wallis analyses were used to assess between-group differences at baseline.

Results: From 2011 to 2015, 478 (103%) of a targeted 464 patients were randomized at 91 study sites. At baseline, mean (SD) age was 64 (6) years and PSA 4.9 (2.1) ng/mL. Fifty-six (12%) participants were African-American, 17 (4%) Hispanic/Latino, and 16 (3%) Asian-American. There were no significant between-group differences for age (p-value = 0.98), race/ethnicity (p-value = 0.52), geographic region (p-value = 0.60), time since prostate cancer diagnosis (p-value = 0.85), PSA (p-value = 0.96), clinical stage (T1c or T2a, p-value = 0.27), or Gleason sum (Gleason 6 or 3+4 = 7, p-value = 0.76). In a pre-planned analysis, the baseline prostate biopsy samples of the first 50 patients underwent central pathology review to confirm eligibility, with an expectation that <10% would become ineligible. One (2%) of 50 patients became ineligible.

Conclusions: The MEAL Study demonstrates the feasibility of implementing national, multi-institutional phase 3 clinical trials of diet for prostate cancer and of testing interventions to prevent disease progression in active surveillance.

Funding: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under the Award Number UG1CA189823 (Alliance for Clinical Trials in Oncology NCORP Grant), U10CA037447, U10CA011789, U10CA041287, U10CA059518, U10CA077651, U10CA077658, U10CA138561, U10CA180791, U10CA180850, U10CA180866, National Cancer Institute 1R01 CA132951-01A1, Department of Defense PC073412, and The Prostate Cancer Foundation. The study is also supported, in part, by grants from the National Cancer Institute (CA31946) to the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, M.D., Chair) and to the Alliance Statistics and Data Center (Daniel J. Sargent, Ph.D., CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the Department of Defense.